Affiliations
Division of Gastroenterology, University of Arizona, Tucson, Arizona
Given name(s)
John
Family name
Brooling
Degrees
MD

Paracentesis in Cirrhosis Patients/

Article Type
Changed
Mon, 01/02/2017 - 19:34
Display Headline
Use of paracentesis in hospitalized patients with decompensated cirrhosis and ascites: Opportunities for quality improvement

Ascites is the most common complication of cirrhosis leading to hospital admission.[1] Approximately 12% of hospitalized patients who present with decompensated cirrhosis and ascites have spontaneous bacterial peritonitis (SBP); half of these patients do not present with abdominal pain, fever, nausea, or vomiting.[2] Guidelines published by the American Association for the Study of Liver Diseases (AASLD) recommend paracentesis for all hospitalized patients with cirrhosis and ascites and also recommend long‐term antibiotic prophylaxis for survivors of an SBP episode.[3] Despite evidence that in‐hospital mortality is reduced in those patients who receive paracentesis in a timely manner,[4, 5] only 40% to 60% of eligible patients receive paracentesis.[4, 6, 7] We aimed to describe clinical predictors of paracentesis and use of antibiotics following an episode of SBP in patients with decompensated cirrhosis and ascites.

METHODS

We conducted a retrospective cohort study of adults admitted to a single tertiary care center between January 1, 2009 and December 31, 2009.7 We included patients with an International Classification of Diseases, Ninth Revision discharge code consistent with decompensated cirrhosis who met clinical criteria for decompensated cirrhosis (see Supporting Figure 1 in the online version of this article) [7] and had enough ascitic fluid to be sampled under imaging guidance. We collected presenting vital signs, laboratory data (within 24 hours of admission), evidence of infection other than SBP (eg, urinary infection, pneumonia), results of peritoneal fluid analysis (defining SBP as 250 polymorphonuclear leukocytes), and use of antibiotic therapy. Our statistical analysis calculated summary statistics as means, medians, and proportions. Furthermore, we used multiple logistic regression to examine the association between predictors and receipt of paracentesis, including age, sex, and clinical measures associated with paracentesis at P0.20 using the Fisher exact test. Alpha was set at 0.05 (2‐sided) for all comparisons.

RESULTS

We identified 193 admissions for 103 patients with decompensated cirrhosis and ascites (Table 1). Of these, 41% (80/193) received diagnostic paracentesis. Mean/standard deviation for age was 53.6/12.4 years; 71% of patients were male and 63% were English speaking. Common comorbidities included diabetes mellitus (33%), psychiatric diagnosis (29%), substance abuse (18%), and renal failure (17%). Excluding SBP, 31% of patients had another documented infection. Gastroenterology was consulted in 50% of the admissions. Fever was present in 27% of patients, elevated white blood cell (WBC) count (ie, WBC >11 k/mm3) was present in 27% of patients, International Normalized Ratio (INR) was elevated (>1.1) in 92% of patients, and 16% of patients had a platelet count of <50,000/mm3. Patients who received paracentesis were less likely to have a fever on presentation (19% vs 32%, P=0.06), low (ie, <50,000/mm3) platelet count (11% vs 19%, P=0.14), or concurrent gastrointestinal (GI) bleed (6% vs 16%, P=0.05). In a multiple logistic regression model including characteristics associated at P0.2 with paracentesis, fever, low platelet count, and concurrent GI bleeding were associated with decreased odds of receiving paracentesis (Appendix 1).

Characteristics of Patients With Diagnostic Paracentesis and Without Diagnostic Paracentesis
Overall, N=193, Mean/SD or N (%)* Paracentesis (), n=113, Mean/SD or N (%) Paracentesis (+), n=80, Mean/SD or N (%) Odds Ratio (95% CI)
  • NOTE: Abbreviations: CI, confidence interval; GI, gastrointestinal; HR, heart rate; INR, International Normalized Ratio; IQR, interquartile range; MAP, mean arterial pressure; MELD, model for end‐stage liver disease; NASH, nonalcoholic steatohepatitis; O2Sat, oxygen saturation; PT, prothrombin time; RR, respiratory rate; SBP, systolic blood pressure; SD, standard deviation; UTI, urinary tract infection; WBC, white blood cell. *Fever, WBC, temperature, respiratory rate, SBP, MAP, and O2Sat were documented for 183 patients (105 paracentesis patients and 78 nonparacentesis patients). INR was documented for 162 patients (73 paracentesis patients and 89 nonparacentesis patients). PT was documented for 133 patients (59 paracentesis patients and 74 nonparacentesis patients). Platelet count was documented for 189 patients.

Age, y 53.6/12.4 54.1/13.4 53.2/11.7 1.00 (0.981.03)
Sex (male) 137 (71.0%) 78 (69.0%) 59 (73.8%) 1.26 (0.672.39)
English speaking 122 (63.2%) 69 (61.1%) 53 (66.3%) 1.25 (0.692.28)
Etiology
Alcohol 120 (62.2%) 74 (65.5%) 46 (57.5%) 0.71 (0.401.29)
Hepatitis C 94 (48.7%) 57 (50.4%) 37 (46.3%) 0.85 (0.481.50)
Hepatitis B 16 (8.3%) 7 (6.2%) 9 (11.3%) 1.92 (0.685.39)
NASH 8 (4.2%) 4 (3.5%) 4 (5.0%) 1.43 (0.355.91)
Cryptogenic 11 (5.7%) 6 (5.3%) 5 (6.3%) 1.19 (0.354.04)
Comorbidities
Substance abuse 34 (17.6%) 22 (19.5%) 12 (15.0%) 0.73 (0.341.58)
Psychiatric diagnosis 55 (28.5%) 38 (33.6%) 17 (21.3%) 0.53 (0.271.03)
Diabetes mellitus 63 (32.6%) 37 (32.7%) 26 (32.5%) 0.99 (0.541.82)
Renal failure 33 (17.1%) 20 (17.7%) 13 (16.3%) 0.90 (0.421.94)
GI bleed 23 (11.9%) 18 (15.9%) 5 (6.3%) 0.35 (0.120.99)
Admission MELD 17.3/7.3 17.5/7.3 17.0/7.3 0.99 (0.951.03)
Creatinine, median/IQR 0.9/0.7 0.9/0.7 0.9/0.8 1.02 (0.821.27)
Gastroenterology consult 97 (50.3%) 46 (40.7%) 51 (63.8%) 2.56 (1.424.63)
Infection, UTI, pneumonia, other 60 (31.1%) 38 (33.6%) 22 (27.5%) 0.75 (0.401.40)
Temperature 100.4F 49 (26.8%) 34 (32.4%) 15 (19.2%) 0.50 (0.251.00)
WBC >11 k/mm3 50 (27.3%) 28 (26.7%) 22 (28.2%) 1.08 (0.562.08)
WBC <4 k/mm3 43 (23.5%) 23 (21.9%) 20 (25.6%) 1.23 (0.622.44)
INR >1.1 149 (92.0%) 83 (93.3%) 66 (90.4%) 0.68 (0.222.13)
Highest temperature, F 98.9/1.1 99.1/1.3 98.8/0.8 0.82 (0.621.09)
Highest HR 98.2/20.4 97.4/22.4 99.2/17.4 1.00 (0.991.02)
Highest RR 24.5/13.7 25.2/16.8 23.5/7.8 0.99 (0.961.02)
Lowest SBP 101.0/20.0 99.4/20.3 102.2/19.7 0.99 (0.981.01)
Lowest MAP 73.0/12.2 73.2/13.3 72.7/10.6 1.00 (0.971.02)
Lowest O2Sat 92.6/13.6 91.0/17.7 94.9/2.8 1.04 (0.991.10)
Highest PT 15.8/3.8 15.9/3.7 15.7/3.9 0.98 (0.901.08)
Platelets 50 k/mm3 30 (15.9%) 21 (19.3%) 9 (11.3%) 0.53 (0.231.23)

Of the patients who received paracentesis (n=80), 14% were diagnosed with SBP. Of these, 55% received prophylaxis on discharge. Among the patients who did not receive paracentesis (n=113), 38 (34%) received antibiotics for another documented infection (eg, pneumonia), and 25 patients (22%) received antibiotics with no other documented infection or evidence of variceal bleeding. Of these 25 patients who were presumed to be empirically treated for SBP (Figure 1), only 20% were prescribed prophylactic antibiotics on discharge.

Figure 1
The pie chart on the left displays the percentage of patients in each group who did not receive paracentesis (red = no antibiotics, dark blue = receiving antibiotics for another infection, light blue = receiving antibiotics with no other infection). The pie chart on the right displays the light blue group and whether they were discharged on antibiotics (green) or not (purple).

CONCLUSION

We found that many patients with decompensated cirrhosis and ascites did not receive paracentesis when hospitalized, which is similar to previously published data.[4, 6, 7] Clinical evidence of infection, such as fever or elevated WBC count, did not increase the odds of receiving paracentesis. Many patients treated for SBP were not discharged on prophylaxis.

This study is limited by its small single‐center design. We could only use data from 1 year (2009), because study data collection was part of a quality‐improvement project that took place for that year only. We did not adjust for the number of red blood cells in the ascitic fluid samples. We were also unable to determine the timing of gastroenterology consultation (whether it was done prior to paracentesis), admission venue (floor vs intensive care), or patient history of SBP.

Despite these limitations, there are important implications. First, the decision to perform paracentesis was not associated with symptoms of infection, although some clinical factors (eg, low platelets or GI bleeding) were associated with reduced odds of receiving paracentesis. Second, a majority of patients treated for SBP did not receive prophylactic antibiotics at discharge. These findings suggest a clear opportunity to increase awareness and acceptance of AASLD guidelines among hospital medicine practitioners. Quality‐improvement efforts should focus on the education of providers, and future research should identify barriers to paracentesis at both the practitioner and system levels (eg, availability of interventional radiology). Checklists or decision support within electronic order entry systems may also help reduce the low rates of paracentesis seen in our and prior studies.[4, 6, 7]

Disclosures: Dr. Lagu is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number K01HL114745. Drs. Lagu, Ghaoui, and Brooling had full access to all of the data in the study. They take responsibility for the integrity of the data and the accuracy of the data analysis. Drs. Lagu, Ghaoui, and Brooling conceived of the study. Dr. Ghaoui acquired the data. Ms. Friderici carried out the statistical analyses. Drs. Lagu, Ghaoui, Brooling, Lindenauer, and Ms. Friderici analyzed and interpreted the data, drafted the manuscript, and critically reviewed the manuscript for important intellectual content. The authors report no conflicts of interest.

Files
References
  1. Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, De La Cuesta FS; Spanish Collaborative Study Group On Therapeutic Management In Liver Disease. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol. 2002;58(6):435440.
  2. Borzio M, Salerno F, Piantoni L, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis. 2001;33(1):4148.
  3. Runyon BA, AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):16511653.
  4. Orman ES, Hayashi PH, Bataller R, Barritt AS. Paracentesis is associated with reduced mortality in patients hospitalized with cirrhosis and ascites. Clin Gastroenterol Hepatol. 2014;12(3):496503.e1.
  5. Kim JJ, Tsukamoto MM, Mathur AK, et al. Delayed paracentesis is associated with increased in‐hospital mortality in patients with spontaneous bacterial peritonitis. Am J Gastroenterol. 2014;109(9):14361442.
  6. Kanwal F, Kramer JR, Buchanan P, et al. The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs. Gastroenterology. 2012;143(1):7077.
  7. Ghaoui R, Friderici J, Visintainer PK, Lindenauer P, Lagu T, Desilets D. Measurement of the quality of care of patients admitted with decompensated cirrhosis. Liver Int. 2014;34(2):204210.
Article PDF
Issue
Journal of Hospital Medicine - 9(12)
Publications
Page Number
797-799
Sections
Files
Files
Article PDF
Article PDF

Ascites is the most common complication of cirrhosis leading to hospital admission.[1] Approximately 12% of hospitalized patients who present with decompensated cirrhosis and ascites have spontaneous bacterial peritonitis (SBP); half of these patients do not present with abdominal pain, fever, nausea, or vomiting.[2] Guidelines published by the American Association for the Study of Liver Diseases (AASLD) recommend paracentesis for all hospitalized patients with cirrhosis and ascites and also recommend long‐term antibiotic prophylaxis for survivors of an SBP episode.[3] Despite evidence that in‐hospital mortality is reduced in those patients who receive paracentesis in a timely manner,[4, 5] only 40% to 60% of eligible patients receive paracentesis.[4, 6, 7] We aimed to describe clinical predictors of paracentesis and use of antibiotics following an episode of SBP in patients with decompensated cirrhosis and ascites.

METHODS

We conducted a retrospective cohort study of adults admitted to a single tertiary care center between January 1, 2009 and December 31, 2009.7 We included patients with an International Classification of Diseases, Ninth Revision discharge code consistent with decompensated cirrhosis who met clinical criteria for decompensated cirrhosis (see Supporting Figure 1 in the online version of this article) [7] and had enough ascitic fluid to be sampled under imaging guidance. We collected presenting vital signs, laboratory data (within 24 hours of admission), evidence of infection other than SBP (eg, urinary infection, pneumonia), results of peritoneal fluid analysis (defining SBP as 250 polymorphonuclear leukocytes), and use of antibiotic therapy. Our statistical analysis calculated summary statistics as means, medians, and proportions. Furthermore, we used multiple logistic regression to examine the association between predictors and receipt of paracentesis, including age, sex, and clinical measures associated with paracentesis at P0.20 using the Fisher exact test. Alpha was set at 0.05 (2‐sided) for all comparisons.

RESULTS

We identified 193 admissions for 103 patients with decompensated cirrhosis and ascites (Table 1). Of these, 41% (80/193) received diagnostic paracentesis. Mean/standard deviation for age was 53.6/12.4 years; 71% of patients were male and 63% were English speaking. Common comorbidities included diabetes mellitus (33%), psychiatric diagnosis (29%), substance abuse (18%), and renal failure (17%). Excluding SBP, 31% of patients had another documented infection. Gastroenterology was consulted in 50% of the admissions. Fever was present in 27% of patients, elevated white blood cell (WBC) count (ie, WBC >11 k/mm3) was present in 27% of patients, International Normalized Ratio (INR) was elevated (>1.1) in 92% of patients, and 16% of patients had a platelet count of <50,000/mm3. Patients who received paracentesis were less likely to have a fever on presentation (19% vs 32%, P=0.06), low (ie, <50,000/mm3) platelet count (11% vs 19%, P=0.14), or concurrent gastrointestinal (GI) bleed (6% vs 16%, P=0.05). In a multiple logistic regression model including characteristics associated at P0.2 with paracentesis, fever, low platelet count, and concurrent GI bleeding were associated with decreased odds of receiving paracentesis (Appendix 1).

Characteristics of Patients With Diagnostic Paracentesis and Without Diagnostic Paracentesis
Overall, N=193, Mean/SD or N (%)* Paracentesis (), n=113, Mean/SD or N (%) Paracentesis (+), n=80, Mean/SD or N (%) Odds Ratio (95% CI)
  • NOTE: Abbreviations: CI, confidence interval; GI, gastrointestinal; HR, heart rate; INR, International Normalized Ratio; IQR, interquartile range; MAP, mean arterial pressure; MELD, model for end‐stage liver disease; NASH, nonalcoholic steatohepatitis; O2Sat, oxygen saturation; PT, prothrombin time; RR, respiratory rate; SBP, systolic blood pressure; SD, standard deviation; UTI, urinary tract infection; WBC, white blood cell. *Fever, WBC, temperature, respiratory rate, SBP, MAP, and O2Sat were documented for 183 patients (105 paracentesis patients and 78 nonparacentesis patients). INR was documented for 162 patients (73 paracentesis patients and 89 nonparacentesis patients). PT was documented for 133 patients (59 paracentesis patients and 74 nonparacentesis patients). Platelet count was documented for 189 patients.

Age, y 53.6/12.4 54.1/13.4 53.2/11.7 1.00 (0.981.03)
Sex (male) 137 (71.0%) 78 (69.0%) 59 (73.8%) 1.26 (0.672.39)
English speaking 122 (63.2%) 69 (61.1%) 53 (66.3%) 1.25 (0.692.28)
Etiology
Alcohol 120 (62.2%) 74 (65.5%) 46 (57.5%) 0.71 (0.401.29)
Hepatitis C 94 (48.7%) 57 (50.4%) 37 (46.3%) 0.85 (0.481.50)
Hepatitis B 16 (8.3%) 7 (6.2%) 9 (11.3%) 1.92 (0.685.39)
NASH 8 (4.2%) 4 (3.5%) 4 (5.0%) 1.43 (0.355.91)
Cryptogenic 11 (5.7%) 6 (5.3%) 5 (6.3%) 1.19 (0.354.04)
Comorbidities
Substance abuse 34 (17.6%) 22 (19.5%) 12 (15.0%) 0.73 (0.341.58)
Psychiatric diagnosis 55 (28.5%) 38 (33.6%) 17 (21.3%) 0.53 (0.271.03)
Diabetes mellitus 63 (32.6%) 37 (32.7%) 26 (32.5%) 0.99 (0.541.82)
Renal failure 33 (17.1%) 20 (17.7%) 13 (16.3%) 0.90 (0.421.94)
GI bleed 23 (11.9%) 18 (15.9%) 5 (6.3%) 0.35 (0.120.99)
Admission MELD 17.3/7.3 17.5/7.3 17.0/7.3 0.99 (0.951.03)
Creatinine, median/IQR 0.9/0.7 0.9/0.7 0.9/0.8 1.02 (0.821.27)
Gastroenterology consult 97 (50.3%) 46 (40.7%) 51 (63.8%) 2.56 (1.424.63)
Infection, UTI, pneumonia, other 60 (31.1%) 38 (33.6%) 22 (27.5%) 0.75 (0.401.40)
Temperature 100.4F 49 (26.8%) 34 (32.4%) 15 (19.2%) 0.50 (0.251.00)
WBC >11 k/mm3 50 (27.3%) 28 (26.7%) 22 (28.2%) 1.08 (0.562.08)
WBC <4 k/mm3 43 (23.5%) 23 (21.9%) 20 (25.6%) 1.23 (0.622.44)
INR >1.1 149 (92.0%) 83 (93.3%) 66 (90.4%) 0.68 (0.222.13)
Highest temperature, F 98.9/1.1 99.1/1.3 98.8/0.8 0.82 (0.621.09)
Highest HR 98.2/20.4 97.4/22.4 99.2/17.4 1.00 (0.991.02)
Highest RR 24.5/13.7 25.2/16.8 23.5/7.8 0.99 (0.961.02)
Lowest SBP 101.0/20.0 99.4/20.3 102.2/19.7 0.99 (0.981.01)
Lowest MAP 73.0/12.2 73.2/13.3 72.7/10.6 1.00 (0.971.02)
Lowest O2Sat 92.6/13.6 91.0/17.7 94.9/2.8 1.04 (0.991.10)
Highest PT 15.8/3.8 15.9/3.7 15.7/3.9 0.98 (0.901.08)
Platelets 50 k/mm3 30 (15.9%) 21 (19.3%) 9 (11.3%) 0.53 (0.231.23)

Of the patients who received paracentesis (n=80), 14% were diagnosed with SBP. Of these, 55% received prophylaxis on discharge. Among the patients who did not receive paracentesis (n=113), 38 (34%) received antibiotics for another documented infection (eg, pneumonia), and 25 patients (22%) received antibiotics with no other documented infection or evidence of variceal bleeding. Of these 25 patients who were presumed to be empirically treated for SBP (Figure 1), only 20% were prescribed prophylactic antibiotics on discharge.

Figure 1
The pie chart on the left displays the percentage of patients in each group who did not receive paracentesis (red = no antibiotics, dark blue = receiving antibiotics for another infection, light blue = receiving antibiotics with no other infection). The pie chart on the right displays the light blue group and whether they were discharged on antibiotics (green) or not (purple).

CONCLUSION

We found that many patients with decompensated cirrhosis and ascites did not receive paracentesis when hospitalized, which is similar to previously published data.[4, 6, 7] Clinical evidence of infection, such as fever or elevated WBC count, did not increase the odds of receiving paracentesis. Many patients treated for SBP were not discharged on prophylaxis.

This study is limited by its small single‐center design. We could only use data from 1 year (2009), because study data collection was part of a quality‐improvement project that took place for that year only. We did not adjust for the number of red blood cells in the ascitic fluid samples. We were also unable to determine the timing of gastroenterology consultation (whether it was done prior to paracentesis), admission venue (floor vs intensive care), or patient history of SBP.

Despite these limitations, there are important implications. First, the decision to perform paracentesis was not associated with symptoms of infection, although some clinical factors (eg, low platelets or GI bleeding) were associated with reduced odds of receiving paracentesis. Second, a majority of patients treated for SBP did not receive prophylactic antibiotics at discharge. These findings suggest a clear opportunity to increase awareness and acceptance of AASLD guidelines among hospital medicine practitioners. Quality‐improvement efforts should focus on the education of providers, and future research should identify barriers to paracentesis at both the practitioner and system levels (eg, availability of interventional radiology). Checklists or decision support within electronic order entry systems may also help reduce the low rates of paracentesis seen in our and prior studies.[4, 6, 7]

Disclosures: Dr. Lagu is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number K01HL114745. Drs. Lagu, Ghaoui, and Brooling had full access to all of the data in the study. They take responsibility for the integrity of the data and the accuracy of the data analysis. Drs. Lagu, Ghaoui, and Brooling conceived of the study. Dr. Ghaoui acquired the data. Ms. Friderici carried out the statistical analyses. Drs. Lagu, Ghaoui, Brooling, Lindenauer, and Ms. Friderici analyzed and interpreted the data, drafted the manuscript, and critically reviewed the manuscript for important intellectual content. The authors report no conflicts of interest.

Ascites is the most common complication of cirrhosis leading to hospital admission.[1] Approximately 12% of hospitalized patients who present with decompensated cirrhosis and ascites have spontaneous bacterial peritonitis (SBP); half of these patients do not present with abdominal pain, fever, nausea, or vomiting.[2] Guidelines published by the American Association for the Study of Liver Diseases (AASLD) recommend paracentesis for all hospitalized patients with cirrhosis and ascites and also recommend long‐term antibiotic prophylaxis for survivors of an SBP episode.[3] Despite evidence that in‐hospital mortality is reduced in those patients who receive paracentesis in a timely manner,[4, 5] only 40% to 60% of eligible patients receive paracentesis.[4, 6, 7] We aimed to describe clinical predictors of paracentesis and use of antibiotics following an episode of SBP in patients with decompensated cirrhosis and ascites.

METHODS

We conducted a retrospective cohort study of adults admitted to a single tertiary care center between January 1, 2009 and December 31, 2009.7 We included patients with an International Classification of Diseases, Ninth Revision discharge code consistent with decompensated cirrhosis who met clinical criteria for decompensated cirrhosis (see Supporting Figure 1 in the online version of this article) [7] and had enough ascitic fluid to be sampled under imaging guidance. We collected presenting vital signs, laboratory data (within 24 hours of admission), evidence of infection other than SBP (eg, urinary infection, pneumonia), results of peritoneal fluid analysis (defining SBP as 250 polymorphonuclear leukocytes), and use of antibiotic therapy. Our statistical analysis calculated summary statistics as means, medians, and proportions. Furthermore, we used multiple logistic regression to examine the association between predictors and receipt of paracentesis, including age, sex, and clinical measures associated with paracentesis at P0.20 using the Fisher exact test. Alpha was set at 0.05 (2‐sided) for all comparisons.

RESULTS

We identified 193 admissions for 103 patients with decompensated cirrhosis and ascites (Table 1). Of these, 41% (80/193) received diagnostic paracentesis. Mean/standard deviation for age was 53.6/12.4 years; 71% of patients were male and 63% were English speaking. Common comorbidities included diabetes mellitus (33%), psychiatric diagnosis (29%), substance abuse (18%), and renal failure (17%). Excluding SBP, 31% of patients had another documented infection. Gastroenterology was consulted in 50% of the admissions. Fever was present in 27% of patients, elevated white blood cell (WBC) count (ie, WBC >11 k/mm3) was present in 27% of patients, International Normalized Ratio (INR) was elevated (>1.1) in 92% of patients, and 16% of patients had a platelet count of <50,000/mm3. Patients who received paracentesis were less likely to have a fever on presentation (19% vs 32%, P=0.06), low (ie, <50,000/mm3) platelet count (11% vs 19%, P=0.14), or concurrent gastrointestinal (GI) bleed (6% vs 16%, P=0.05). In a multiple logistic regression model including characteristics associated at P0.2 with paracentesis, fever, low platelet count, and concurrent GI bleeding were associated with decreased odds of receiving paracentesis (Appendix 1).

Characteristics of Patients With Diagnostic Paracentesis and Without Diagnostic Paracentesis
Overall, N=193, Mean/SD or N (%)* Paracentesis (), n=113, Mean/SD or N (%) Paracentesis (+), n=80, Mean/SD or N (%) Odds Ratio (95% CI)
  • NOTE: Abbreviations: CI, confidence interval; GI, gastrointestinal; HR, heart rate; INR, International Normalized Ratio; IQR, interquartile range; MAP, mean arterial pressure; MELD, model for end‐stage liver disease; NASH, nonalcoholic steatohepatitis; O2Sat, oxygen saturation; PT, prothrombin time; RR, respiratory rate; SBP, systolic blood pressure; SD, standard deviation; UTI, urinary tract infection; WBC, white blood cell. *Fever, WBC, temperature, respiratory rate, SBP, MAP, and O2Sat were documented for 183 patients (105 paracentesis patients and 78 nonparacentesis patients). INR was documented for 162 patients (73 paracentesis patients and 89 nonparacentesis patients). PT was documented for 133 patients (59 paracentesis patients and 74 nonparacentesis patients). Platelet count was documented for 189 patients.

Age, y 53.6/12.4 54.1/13.4 53.2/11.7 1.00 (0.981.03)
Sex (male) 137 (71.0%) 78 (69.0%) 59 (73.8%) 1.26 (0.672.39)
English speaking 122 (63.2%) 69 (61.1%) 53 (66.3%) 1.25 (0.692.28)
Etiology
Alcohol 120 (62.2%) 74 (65.5%) 46 (57.5%) 0.71 (0.401.29)
Hepatitis C 94 (48.7%) 57 (50.4%) 37 (46.3%) 0.85 (0.481.50)
Hepatitis B 16 (8.3%) 7 (6.2%) 9 (11.3%) 1.92 (0.685.39)
NASH 8 (4.2%) 4 (3.5%) 4 (5.0%) 1.43 (0.355.91)
Cryptogenic 11 (5.7%) 6 (5.3%) 5 (6.3%) 1.19 (0.354.04)
Comorbidities
Substance abuse 34 (17.6%) 22 (19.5%) 12 (15.0%) 0.73 (0.341.58)
Psychiatric diagnosis 55 (28.5%) 38 (33.6%) 17 (21.3%) 0.53 (0.271.03)
Diabetes mellitus 63 (32.6%) 37 (32.7%) 26 (32.5%) 0.99 (0.541.82)
Renal failure 33 (17.1%) 20 (17.7%) 13 (16.3%) 0.90 (0.421.94)
GI bleed 23 (11.9%) 18 (15.9%) 5 (6.3%) 0.35 (0.120.99)
Admission MELD 17.3/7.3 17.5/7.3 17.0/7.3 0.99 (0.951.03)
Creatinine, median/IQR 0.9/0.7 0.9/0.7 0.9/0.8 1.02 (0.821.27)
Gastroenterology consult 97 (50.3%) 46 (40.7%) 51 (63.8%) 2.56 (1.424.63)
Infection, UTI, pneumonia, other 60 (31.1%) 38 (33.6%) 22 (27.5%) 0.75 (0.401.40)
Temperature 100.4F 49 (26.8%) 34 (32.4%) 15 (19.2%) 0.50 (0.251.00)
WBC >11 k/mm3 50 (27.3%) 28 (26.7%) 22 (28.2%) 1.08 (0.562.08)
WBC <4 k/mm3 43 (23.5%) 23 (21.9%) 20 (25.6%) 1.23 (0.622.44)
INR >1.1 149 (92.0%) 83 (93.3%) 66 (90.4%) 0.68 (0.222.13)
Highest temperature, F 98.9/1.1 99.1/1.3 98.8/0.8 0.82 (0.621.09)
Highest HR 98.2/20.4 97.4/22.4 99.2/17.4 1.00 (0.991.02)
Highest RR 24.5/13.7 25.2/16.8 23.5/7.8 0.99 (0.961.02)
Lowest SBP 101.0/20.0 99.4/20.3 102.2/19.7 0.99 (0.981.01)
Lowest MAP 73.0/12.2 73.2/13.3 72.7/10.6 1.00 (0.971.02)
Lowest O2Sat 92.6/13.6 91.0/17.7 94.9/2.8 1.04 (0.991.10)
Highest PT 15.8/3.8 15.9/3.7 15.7/3.9 0.98 (0.901.08)
Platelets 50 k/mm3 30 (15.9%) 21 (19.3%) 9 (11.3%) 0.53 (0.231.23)

Of the patients who received paracentesis (n=80), 14% were diagnosed with SBP. Of these, 55% received prophylaxis on discharge. Among the patients who did not receive paracentesis (n=113), 38 (34%) received antibiotics for another documented infection (eg, pneumonia), and 25 patients (22%) received antibiotics with no other documented infection or evidence of variceal bleeding. Of these 25 patients who were presumed to be empirically treated for SBP (Figure 1), only 20% were prescribed prophylactic antibiotics on discharge.

Figure 1
The pie chart on the left displays the percentage of patients in each group who did not receive paracentesis (red = no antibiotics, dark blue = receiving antibiotics for another infection, light blue = receiving antibiotics with no other infection). The pie chart on the right displays the light blue group and whether they were discharged on antibiotics (green) or not (purple).

CONCLUSION

We found that many patients with decompensated cirrhosis and ascites did not receive paracentesis when hospitalized, which is similar to previously published data.[4, 6, 7] Clinical evidence of infection, such as fever or elevated WBC count, did not increase the odds of receiving paracentesis. Many patients treated for SBP were not discharged on prophylaxis.

This study is limited by its small single‐center design. We could only use data from 1 year (2009), because study data collection was part of a quality‐improvement project that took place for that year only. We did not adjust for the number of red blood cells in the ascitic fluid samples. We were also unable to determine the timing of gastroenterology consultation (whether it was done prior to paracentesis), admission venue (floor vs intensive care), or patient history of SBP.

Despite these limitations, there are important implications. First, the decision to perform paracentesis was not associated with symptoms of infection, although some clinical factors (eg, low platelets or GI bleeding) were associated with reduced odds of receiving paracentesis. Second, a majority of patients treated for SBP did not receive prophylactic antibiotics at discharge. These findings suggest a clear opportunity to increase awareness and acceptance of AASLD guidelines among hospital medicine practitioners. Quality‐improvement efforts should focus on the education of providers, and future research should identify barriers to paracentesis at both the practitioner and system levels (eg, availability of interventional radiology). Checklists or decision support within electronic order entry systems may also help reduce the low rates of paracentesis seen in our and prior studies.[4, 6, 7]

Disclosures: Dr. Lagu is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number K01HL114745. Drs. Lagu, Ghaoui, and Brooling had full access to all of the data in the study. They take responsibility for the integrity of the data and the accuracy of the data analysis. Drs. Lagu, Ghaoui, and Brooling conceived of the study. Dr. Ghaoui acquired the data. Ms. Friderici carried out the statistical analyses. Drs. Lagu, Ghaoui, Brooling, Lindenauer, and Ms. Friderici analyzed and interpreted the data, drafted the manuscript, and critically reviewed the manuscript for important intellectual content. The authors report no conflicts of interest.

References
  1. Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, De La Cuesta FS; Spanish Collaborative Study Group On Therapeutic Management In Liver Disease. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol. 2002;58(6):435440.
  2. Borzio M, Salerno F, Piantoni L, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis. 2001;33(1):4148.
  3. Runyon BA, AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):16511653.
  4. Orman ES, Hayashi PH, Bataller R, Barritt AS. Paracentesis is associated with reduced mortality in patients hospitalized with cirrhosis and ascites. Clin Gastroenterol Hepatol. 2014;12(3):496503.e1.
  5. Kim JJ, Tsukamoto MM, Mathur AK, et al. Delayed paracentesis is associated with increased in‐hospital mortality in patients with spontaneous bacterial peritonitis. Am J Gastroenterol. 2014;109(9):14361442.
  6. Kanwal F, Kramer JR, Buchanan P, et al. The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs. Gastroenterology. 2012;143(1):7077.
  7. Ghaoui R, Friderici J, Visintainer PK, Lindenauer P, Lagu T, Desilets D. Measurement of the quality of care of patients admitted with decompensated cirrhosis. Liver Int. 2014;34(2):204210.
References
  1. Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, De La Cuesta FS; Spanish Collaborative Study Group On Therapeutic Management In Liver Disease. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol. 2002;58(6):435440.
  2. Borzio M, Salerno F, Piantoni L, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis. 2001;33(1):4148.
  3. Runyon BA, AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):16511653.
  4. Orman ES, Hayashi PH, Bataller R, Barritt AS. Paracentesis is associated with reduced mortality in patients hospitalized with cirrhosis and ascites. Clin Gastroenterol Hepatol. 2014;12(3):496503.e1.
  5. Kim JJ, Tsukamoto MM, Mathur AK, et al. Delayed paracentesis is associated with increased in‐hospital mortality in patients with spontaneous bacterial peritonitis. Am J Gastroenterol. 2014;109(9):14361442.
  6. Kanwal F, Kramer JR, Buchanan P, et al. The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs. Gastroenterology. 2012;143(1):7077.
  7. Ghaoui R, Friderici J, Visintainer PK, Lindenauer P, Lagu T, Desilets D. Measurement of the quality of care of patients admitted with decompensated cirrhosis. Liver Int. 2014;34(2):204210.
Issue
Journal of Hospital Medicine - 9(12)
Issue
Journal of Hospital Medicine - 9(12)
Page Number
797-799
Page Number
797-799
Publications
Publications
Article Type
Display Headline
Use of paracentesis in hospitalized patients with decompensated cirrhosis and ascites: Opportunities for quality improvement
Display Headline
Use of paracentesis in hospitalized patients with decompensated cirrhosis and ascites: Opportunities for quality improvement
Sections
Article Source
© 2014 Society of Hospital Medicine
Disallow All Ads
Correspondence Location
Address for correspondence and reprint requests: Tara Lagu, MD, Center for Quality of Care Research, Baystate Medical Center, 280 Chestnut Street, Springfield, MA 01199; Telephone: 413–794‐7688; Fax: 413–794‐8866; E‐mail: lagutc@gmail.com
Content Gating
Gated (full article locked unless allowed per User)
Gating Strategy
First Peek Free
Article PDF Media
Media Files